The tauopathies are a group of disorders characterised by aggregation of the microtubuleassociated protein tau and include Alzheimer's disease (AD) and the fronto-temporal dementias (FTD). We have used Drosophila to analyse how tau abnormalities cause neurodegeneration. By selectively co-expressing wild-type human tau (0N3R isoform) and a GFP vesicle marker in motorneurons, we examined the consequences of tau overexpression on axonal transport in vivo. The results show that overexpression of tau disrupts axonal transport causing vesicle aggregation and this is associated with loss of locomotor function. All these effects occur without neuron death. Co-expression of constitutively active glycogensynthase kinase-3b (GSK-3b) enhances and two GSK-3b inhibitors, lithium and AR-A014418, reverse both the axon transport and locomotor phenotypes, suggesting that the pathological effects of tau are phosphorylation dependent. These data show that tau abnormalities significantly disrupt neuronal function, in a phosphorylation-dependent manner, before the classical pathological hallmarks are evident and also suggest that the inhibition of GSK-3b might have potential therapeutic benefits in tauopathies. Keywords: Alzheimer's disease; axonal transport; Drosophila; GSK-3b; lithium; tau Tauopathies are a group of neurodegenerative diseases, including Alzheimer's disease (AD) and the fronto-temporal dementias (FTD), characterised by aggregation of the microtubule-associated protein, tau, into neurofibrillary tangles (NFTs). The finding that mutations in the tau gene give rise to familial FTD 1 proved that abnormalities in tau are sufficient to cause neurodegeneration. However, the cellular mechanisms by which tau abnormalities disrupt neuronal function and lead to neurodegeneration have not been elucidated. Furthermore, in the tauopathies at least three tau protein abnormalities are observed: hyperphosphorylation, altered expression and filament formation; and it is not clear which of these plays a primary role in the disease process and which is a secondary consequence.
Tauopathies are a group of neurodegenerative diseases, including Alzheimer's disease (AD) and the fronto-temporal dementias (FTD), characterised by aggregation of the microtubule-associated protein, tau, into neurofibrillary tangles (NFTs). The finding that mutations in the tau gene give rise to familial FTD 1 proved that abnormalities in tau are sufficient to cause neurodegeneration. However, the cellular mechanisms by which tau abnormalities disrupt neuronal function and lead to neurodegeneration have not been elucidated. Furthermore, in the tauopathies at least three tau protein abnormalities are observed: hyperphosphorylation, altered expression and filament formation; and it is not clear which of these plays a primary role in the disease process and which is a secondary consequence.
We have previously demonstrated that overexpression of tau causes neurodegeneration in Drosophila without forming filamentous aggregates. 2 Others have subsequently confirmed and extended these findings by illustrating that overexpression of FTDP-17 mutant tau also induces neurodegeneration in Drosophila without the formation of neurofibrillary aggregates. 3 More recently it has been shown that hyperphosphorylation of overexpressed tau not only exacerbates the neurodegeneration seen with tau alone but also stimulates filament formation leading to NFT formation in Drosophila. 4 These findings collectively demonstrate that although hyperphosphorylation, and possibly filament formation, can exacerbate taumediated neurodegeneration, overexpression of wildtype (wt) tau alone is sufficient to cause neurodegeneration. The molecular events underlying this have not been elucidated.
There are many ways by which tau overexpression could disrupt neuronal homeostasis and cause neurodegeneration. One possible mechanism is through the disruption of axonal transport. In vitro studies have shown that tau interferes with kinesin activation 5 and disrupts the transport of various kinesin cargoes. [6] [7] [8] Drosophila provides an excellent model organism in which to test this hypothesis, not least because there are Drosophila mutations that affect axonal transport with established phenotypes, for example, kinesin mutants, 9 dynein mutants, 10 kinesin-associated protein mutants (Sunday Driver) 11 and dynein-associated protein mutants (Roadblock). 12 Most of these mutations exhibit larval locomotor defects, which include paralysis in the posterior segments, sluggish locomotion and a characteristic curling of the posterior end called 'tail flipping' caused by paralysis of the dorsal musculature. [9] [10] [11] 13, 14 Given the robustness of these phenotypes we hypothesised that if tau overexpression does disrupt axonal transport, then tau-expressing larvae should exhibit similar locomotor phenotypes. To test this we have developed a simple Drosophila system to examine the effects of tau overexpression on axonal transport and neuron function. To do this we used a motor neuron specific GAL4 driver line (D42) to selectively target the expression of tau and a green fluorescent protein (GFP) marker of transport vesicles in motor neurons. This system has several advantages: motor neurons are accessible for imaging in live intact animals and with the GFP marker it is possible to image axonal transport in live and intact animals. Furthermore, this system provides an assay for the effects of tau on locomotor behaviour to provide a simple readout of the physiological significance of any impairment that tau overexpression may cause.
Materials and methods

Fly strains and crosses
All experiments were performed using the D42 GAL4 enhancer-trap line. We used five GAL4 responder lines: UAS-CD8GFP that encodes a membrane targeted GFP, PU32M2 that encodes a GFP/neuropeptide Y fusion protein that is targeted to transport vesicles (called vGFP), UAS-sggS9A that encodes for a constitutively active form of the Drosophila glycogensynthase kinase-3 (GSK-3b) homolog shaggy (sgg*) and human UAS-0N3R tau and human UAS-4R tau. The PU32M2 line was provided by Dr Iain Robinson (Cambridge University, UK) and the UAS-sgg9A and UAS-0N3R tau lines were obtained from Bloomington Stock Centre, Indiana, USA. The UAS-4R tau line was kindly provided by Dr Makis Skoulakis (Institute of Molecular Biology and Genetics, Vari, Greece). All stocks and crosses were maintained at 251C. To facilitate these studies the PU32M2 transgene was recombined onto the same chromosome as the D42 GAL4 driver using standard genetic techniques. The PU32M2. D42 flies were either used alone (vGFP) or crossed with the UAS-0N3R tau-encoding flies (vGFP Â tau). Standard genetic techniques were also used to generate a fly stock containing both UAS-0N3R tau and UAS-sgg9A. These were crossed with the vGFP flies for some experiments (referred to as vGFP Â tau/sgg*).
Immunohistochemistry
Wandering third instar larvae were dissected for immunocytochemistry keeping the CNS in situ and fixed with 4% paraformaldehyde for 1 h at room temperature. Tissues were processed for immunocytochemistry as previously described. 15 Tissues were incubated in either mouse anti-GFP (Roche Diagnostics, UK) (1 in 200) or rabbit anti-tau (Dako, Denmark) (1 in 1000).
Axonal transport analysis
Axonal transport in living larvae was visualised using a Zeiss Axiophot microscope and a Micromax digital camera (Roper Scientific). Time-lapse images were acquired using Â 63 and Â 100 oil immersion objective from anaesthetised third instar larvae mounted ventral surface up on glass slides. Images were acquired and analysed using Metamorph software (Universal Imaging Corporationt). Images were taken every second for 30 s. At least 20 randomly selected vesicles from each animal were tracked for the duration of the time-lapse video using the 'particle tracker' tool in Metamorph software.
Larval motor function assays
Wandering third instar larvae were used for all larval motor assays. For the 'crawling assay', a track 2 mm wide, 30 mm long and 5 mm deep was created in a 35-mm Petri dish using Sylgard (Dow Corning). The track was moistened with 100 ml of Drosophila saline and fresh yeast placed at the 'finish line' end. Prior to testing, larvae were placed in an identical dummy track and allowed to adapt for 5 min before being transferred to the test track. The time taken to crawl 30 mm to the 'finish line' was recorded for three trials. If during the course of the test the larva turned backwards, it was returned to the starting position and the timing was resumed. For all other larval locomotor assays, larvae were placed on a Petri dish containing 3% agarose and allowed to equilibrate for 120 s before the start of the test. For the 'righting assay', larvae were placed with ventral surfaces upwards and the time taken to return to crawling position was noted. For the 'line crossing assay', the 3% agarose containing Petri dish was placed on a grid with 1 cm 2 boxes and the number of lines crossed by the head of the larvae in 30 s was recorded. For the 'contractions assay', the number of full body peristaltic contractions performed by the larva in 30 s was recorded. Larvae were tested in each locomotor assay three times and the data for the final trial were used in the analysis.
Adult motor function assay Adult locomotion was tested using a modification of the technique developed by Feaney and Bender. 16 
Drug treatment
For experiments in which larvae were treated with lithium or the AR-A014418, fly food, using standard recipes, was made in water containing either 20 mM lithium chloride (LiCl) or 20 mM AR-A014418. AR-A014418 is a thiazole (N-(4-methoxybenzyl)-N 0 -(5-nitro-1,3-thiazol-2-yl) urea) dissolved in water containing 0.1% DMSO. Mating adults were allowed to lay onto this food and their progeny were thus raised on this food until the wandering third instar stage, when they were used for the relevant experiments.
Evidence of cell death Neuromuscular junctions (NMJs) and ventral cords were stained using an anti-GFP antibody as described. 17 The NMJs in abdominal muscles 4, 10 and 12 were examined.
Electron microscopy
The peripheral nervous system of larvae was excised, fixed in 2.5%. paraformaldehyde/2.5% glutaraldehyde, postfixed in 1% osmium tetroxide, and then embedded in taab resin. Once polymerised, the blocks were sequentially ultrathin sectioned at 50 nm section thickness, with sections being taken every 10 mm along the length of the axons (suspected of possessing the pile ups), then stained in uranyl acetate and lead citrate. Low-power electronmicrographs were taken at Â 3500, and high power (EMs) taken at Â 11 000.
Statistical analyses
The paired, two tail Student's t-test was used for most of the statistical analyses unless otherwise stated.
Results
Tau-expressing larvae exhibit locomotor phenotypes that are reminiscent of kinesin mutants Direct observation of larval locomotion showed that all tau-expressing larvae exhibited a clear locomotor dysfunction (see Movies I and II (Supplementary material)). The most severely affected larvae showed complete paralysis of the posterior end and the tail flipping phenotype. Less affected individuals exhibited varying degrees of paralysis but no tail flipping. These phenotypes were qualitatively similar to those described for mutations with known disruptions in axonal transport.
To quantify the locomotor dysfunction, a simple measure of locomotor function was designed called the 'crawling assay'. In this assay, the time taken for late third instar larvae to crawl over a 30-mm track was recorded. Larvae with four different genotypes were tested: (1) Oregon-R (wt control); (2) larvae expressing GFP-targeted to transport vesicles (vGFP) only in motor neurons (control for the D42 GAL4 driver and the UAS-vGFP inserts, and the expression of vGFP in motor neurons); (3) larvae containing an unexpressed UAS-human 0N3R tau transgene (unexpressed tau-control for the UAS-human 0N3R tau gene insertion site) and (4) larvae containing: D42 GAL4 driver, UAS-vGFP and UAS-human 0N3R tau and therefore expressing tau and vGFP in motor neurons (tau expressing-vGFP Â tau). The results of this show that larvae expressing tau and vGFP took significantly longer to complete the crawling task than the wt controls (Po0.001; n ¼ 19 and 16 respectively) and both the vGFP and tau unexpressed controls (Po0.001; n ¼ 19 for both) ( Figure 1a ).
This result suggests that tau expression causes significant locomotor dysfunction. To confirm this three further larval motor function assays were used: Figure 1 Analysis of locomotor function in tau-expressing (vGFP Â tau) and non-tau-expressing larvae. (a) Crawling assay: larvae co-expressing tau and vGFP (vGFP Â tau) took significantly longer to complete the crawling task than both wild-type controls (wt) (Po0.001; n ¼ 19 and 16 respectively) and the non-tau-expressing controls (vGFP and UAStau) (Po0.001; n ¼ 19 for both). (b) Righting assay, (c) line crossing assay and (d) contractions assay. In all cases tauexpressing larvae (vGFP Â tau) were significantly impaired compared to control larvae (Po0.001 for righting assayn ¼ 20; Po0.001 for line crossing assay-n ¼ 10; Po0.001 for contractions assay-n ¼ 10).
(a) the number of peristaltic contractions in 30 s (contractions assay), 18 (b) number of lines crossed by larvae on a grid in 120 s (line crossing assay) and (c) the time taken for larvae placed on their dorsal surface to turn to the ventral surface (righting assay). In all three assays, larvae expressing both tau and vGFP were significantly impaired relative to control larvae expressing vGFP alone (Figure 1b-d) . Impairment was 2.4-fold in the righting assay (Po0.001; n ¼ 20), 1.8-fold in the line crossing assay (Po0.001; n ¼ 10) and 1.6-fold in the contractions assay (Po0.001; n ¼ 10).
Since many of the tau-expressing larvae pupated and eclosed to become viable adults, we were interested in whether the locomotor dysfunction persisted to adult stages. To test locomotion of adult flies a 'climbing assay' was adapted from Feany and Bender 16 Adults were tested in this assay every second day from the first day after eclosion until 36 days post-eclosion. For the first 15 days post-eclosion, there was no significant difference between non-tauexpressing and tau-expressing adults (87% of 5-day non-tau-expressing control flies reached the top chamber compared to 67% of 5-day-old tau-expressing flies). After 15 days, however, the performance of both sets of flies began to deteriorate, but this deterioration was significantly greater in tau-expressing flies (27% of 33-day-old non-tau-expressing control flies reached the top chamber compared to 3% of 33-day-old tau-expressing flies) (ANOVA, n ¼ 10, Po0.05).
Tau induces vesicular aggregations
The locomotor assay results collectively demonstrate that tau expression results in a quantifiable locomotor dysfunction phenotype, which is strikingly reminiscent of the qualitative phenotypes described in Drosophila axonal transport mutants. To evaluate the effect of tau expression on axonal transport more directly we used the expression vesicle targeted vGFP to visualise the distribution of vesicles in tau expressing and non-expressing motor axons.
Wandering third instar larvae were dissected and the GFP-tagged vesicles and tau visualised using immunocytochemistry. In non-tau expressing, control axons, GFP-tagged vesicles were evenly distributed throughout the axons of expressing motor neurons (Figure 2a ). Vesicles were seen throughout the length of the motor axons including the main intersegmental regions, the second-order nerve branches and at the NMJ where they were localised in the boutons (arrowhead in Figure 2a ). In the presence of tau expression, this arrangement of vesicles was severely disrupted (Figure 2b) . Instead of the even distribution that characterised the axons of the control larvae, in tau-expressing axons GFPtagged vesicles accumulated into large axonal swellings that appeared as 'vesicular aggregations' of variable sizes along the length of the axons (arrows in Figure 2b ). The area occupied by vesicular aggregations was quantified and found to be significantly greater in tau over-expressing larvae when compared to the control larvae (Figure 2d ; Po0.001; n ¼ 5). To ensure that the vesicular aggregations were a consequence of tau expression and not attributable to some other aspect in the UAS-tau stock used (these flies express UAS-human 3R tau), these experiments were repeated with another independent UAS human tau isoform insertion stock (UAS-human 4R tau). The expression of the 4R tau induced the formation of vesicular aggregations comparable to those seen with 3R tau (Figure 2d ; Po0.001; n ¼ 3). The effect of tau expression on axonal transport is therefore not secondary to any insertion artifact and occurs with both 3R and 4R isoforms of tau.
The observed vesicular aggregations were remarkably similar to the organelle jams that have been described for known axonal transport mutants. 10, [12] [13] Therefore, these results provide clear in vivo evidence to support the hypothesis that overexpression of wt tau potently inhibits axonal transport.
Over-expression of tau disrupts axonal transport
To study the dynamics of axonal transport in vivo, we visualised vesicle movement in living intact Drosophila. Third instar larvae either expressing GFPtagged vesicles alone or GFP-tagged vesicles and tau were anaesthetised and mounted to allow visualisation of the ventral cord and the peripheral nerves. Owing to the clear cuticle of the larva it is possible to image GFP expressing vesicles in motor axons in intact, live animals. In non-tau-expressing axons the GFP-tagged vesicles were evenly distributed in all neuronal compartments of the motor neurons, including axons (Figure 3a) , dendrites, soma and NMJ boutons (data not shown). All GFP-tagged vesicles were moving anterogradely. Vesicle movements were observed using time lapse imaging acquiring frames at a rate of 2 Hz. Figure 3a shows the movements of vesicles over 4 s (showing every second frame) in a non-tau-expressing axon. On the basis of their movements the GFP-tagged vesicles could be classed into two categories, those that moved rapidly (actual movement range was from 0.5 to -4.4 m ms
À1
) and those that were motile but showed little directional movement (actual movement range was 0-0.4 m ms
). When the axons of motor neurons of tau-expressing living larvae were examined, the vesicular aggregations seen in the fixed tissue were again evident (arrowheads, Figure 3b ) and there were many fewer vesicles than in non-tau-expressing preparations. Although many GFP-tagged vesicles were trapped in the vesicular aggregations, there were vesicles that continued in their axonal transport pathways (arrows, Figure 3b ). See Movies III and IV (Supplementary material).
The velocity of individual randomly selected GFPtagged vesicles in non-tau-expressing larvae was compared to those in tau-expressing larvae. The average velocity of GFP-tagged vesicles in non-tauexpressing larvae (0.502 m ms
, 84 particles tracked in five animals) was not significantly different to that determined for such vesicles in tau-expressing larvae (0.633 m ms
, 91 particles tracked in six animals). These findings demonstrate that although overexpression of tau causes axonal cargoes to accumulate, it does so without affecting the speed of individual vesicles. 
GSK-3b inhibition rescues defects in Drosophila
A Mudher et al Disruption in axonal transport and locomotion in the absence of cell death It is possible that disruption of axonal transport and locomotor phenotypes seen in tau-expressing animals resulted from neuronal death. To evaluate this we examined the NMJ of tau-expressing motor neurons because we predicted that if neuronal death occurred, it would be accompanied by NMJ loss. To visualise NMJs on larval muscles we expressed a membrane targeted CD8GFP in motor neurons using the D42 GAL4 line. Using anti-GFP antibodies the NMJs on muscles 2, 3, 4 and 12 were analysed in third instar larvae that expressed either CD8GFP alone or CD8GFP and tau in motor neurons. The NMJs were observed on all of these muscles in all larvae studied regardless of whether they expressed CD8GFP alone or CD8GFP and tau (n ¼ 20 for both sets).
To further investigate the loss of neurons, we undertook motor neuronal cell body counts. We selected a dorsally placed group of eight uniquely identifiable motor neuron somata, and counted them in five consecutive abdominal segments. The neuronal cell body counts in the tau-expressing larvae were identical to those seen in the control larvae (400 neurons counted in 10 control and 10 tau-expressing larvae).
These data show that all motor neurons are present and that over-expression of tau causes a detectable disruption in axonal transport in the absence of cell death.
Vesicular aggregation and locomotor deficits are exacerbated by tau phosphorylation One mechanism by which tau overexpression may disrupt axonal transport is by aggregating into filaments and physically obstructing the transportation of cargo. We used electron microscopy to examine the vesicular aggregations in three tauexpressing larvae but saw no evidence for inclusion bodies or abnormal filaments (data not shown). It has been shown that simultaneous expression of the tau kinase GSK-3b and human tau stimulates tau aggregation in Drosophila. 4 We therefore generated larvae that were co-expressing human tau and a constitutively active form of the Drosophila homolog of GSK3b (shaggyS9A; sgg*). We then assessed their axonal transport and locomotor abilities and compared them to the phenotypes that were seen in larvae expressing tau alone.
Co-expression of sgg* with human tau exacerbated the locomotor dysfunction seen when tau alone was expressed (as assessed in the 'righting assay'- Figure  4a ; Po0.1; n ¼ 5 and 3). In line with this, vesicular aggregations in larvae co-expressing tau and sgg* were increased by more than three-fold relative to that seen in larvae expressing tau alone (Figure 4b ; Po0.05; n ¼ 4). To confirm that the axonal transport and locomotor phenotypes seen in sgg*-expressing larvae were not attributable to a p-element insertion effect in the sgg* stock, control larvae that contained the sgg* transgene but not the D42 GAL4 driver (and therefore did not express sgg*) were tested in the righting assay and were found to be comparable to the control larvae that were expressing GFP-tagged vesicles only (data not shown).
To test the hypothesis that aggregation of tau in the tau and sgg* co-expressing larvae was causing the axonal transport and locomotor phenotypes, we examined tau expression using immunohistochemistry. Tau was seen to co-localise to the vGFP in the vesicular aggregations, but light microscopy did not reveal any tangle-like structures in the motor neuron axons (n ¼ 4; data not shown). An alternative mechanism by which co-expression of sgg* with tau could cause an exacerbation of the tau phenotype is by inducing hyperphosphorylation of tau. SDS-PAGE gel electrophoresis and western blotting with a phosphospecific anti-tau antibody (tau-1 recognises epitope ser 202 in a non-phosphorylated state) show that tau is hyperphosphorylated in tau and sgg* co-expressing larvae (Figure 4c and d) .
If hyperphosphorylation is the mechanism by which the tau phenotype is exacerbated in tau and Figure 4 Co-expression of tau and sgg* exacerbates tau phenotypes. Overexpression of tau and a constitutively active GSK-3 (shaggy) (vGFP Â tau/sgg*) exacerbates the tau phenotype in: (a) 'righting assay' (P ¼ 0.07 for vGFP Â tau vs vGFP Â tau/sgg*; n ¼ 3 and 5 respectively) (b) the area of vesicular aggregations (P ¼ o0.05 for vGFP Â tau vs vGFP Â tau/sgg*; n ¼ 4). (c) Gel retardation of tau (seen using a non-phosphorylation-dependent anti-tau polyclonal antibody), and (d) reduced immunoreactivity with tau-1 in larvae expressing vGFP Â tau/sgg*. sgg* larvae, then a reduction in tau phosphorylation should rescue the phenotype. To reduce phosphorylation of tau, larvae were reared on food containing 20 mM LiCl, an inhibitor of GSK-3b. 19 Treatment of larvae with LiCl reduced phosphorylation of tau as demonstrated by reduced immunoreactivity using phosphorylation-dependent anti-tau antibodies (12E8 and PHF-1 that recognise tau epitopes ser262/ 356 and ser399/404, respectively, in a phosphorylation-dependent manner) (Figure 5a ). LiCl also rescued both the tau-induced locomotor (Figure 5b ; Po0.01 vGFP Â tau vs vGFP Â tau þ LiCl; n ¼ 20 and 10 respectively) and axonal transport phenotypes (Figure  5c ; Po0.01 vGFP Â tau vs vGFP Â tau þ LiCl; n ¼ 4 and 5 respectively). To confirm that the effect of LiCl was due to inhibition of GSK-3b-mediated phosphorylation of tau, tau-expressing larvae were reared on food that contained another GSK-3b inhibitor-AR-A014418. Like LiCl, AR-A014418 also rescued the tau-mediated locomotor (Figure 5b ; Po0.01 vGFP Â tau vs vGFP Â tau þ AR-A014418; n ¼ 20 for both sets) and axonal transport phenotypes ( Figure  5c ; Po0.1 vGFP Â tau vs vGFP Â tau þ AR-A014418; n ¼ 4 and 3 respectively).
Discussion
The results presented here demonstrate that overexpression of wt tau disrupts axonal transport in vivo leading to a neuronal dysfunction severe enough to manifest a behavioural phenotype in the intact animal. The fact that this effect is apparent before any evidence of cell death suggests that altered expression of tau may compromise neuronal function at an early stage in neurodegeneration. Moreover, these results suggest that hyperphosphorylation of tau may play a primary role in the mechanisms underlying neurodegeneration in the tauopathies, and it can lead to a physiologically significant phenotype that is evident before any sign of filament formation or neuronal death. Phosphorylation of tau by GSK-3b enhances this phenotype, and most importantly, inhibition of endogenous GSK-3b reverses it.
Tau effects on axonal transport
Tau is a microtubule-binding protein, which like other such proteins plays an important role in the maintenance of a stable microtubule cytoskeleton, which in turn provides the tracks along which neuronal axonal transport is effected. Various studies have demonstrated that overexpression of tau results in a disruption of kinesin-mediated transport in a number of different cell types including neurons in vitro. 6, 8, 20 The results presented in this study confirm these findings and extend them to show that overexpression of tau has the same effect in living neurons studied in vivo. There may be two possible mechanisms by which tau mediates this effect: it could detach kinesins and their cargoes from microtubules (possibly by competing for microtubule binding as previously suggested 6 ) or it could reduce kinesin's ATPase activity, 5 and therefore directly reduce the speed of movement such that cargo eventually slow down and get stuck in vesicular aggregations. 7 The fact that overexpression of tau did not affect the actual speed of GFP-tagged vesicles in our system suggests that the former mechanism is operating in this model and that the aggregated vesicles probably represent those that are bound to kinesin but are unable to attach themselves to microtubules. In other words, tau does not actually slow kinesin and its cargoes, but causes cargoes to become detached from microtubules, and hence in this unattached state to aggregate into the pile-ups observed in this study. Moreover, as inhibition of GSK-3b rescues this phenotype our results suggest that if this kinesin competition model is correct, then it is phosphorylated tau that preferentially mediates this effect.
In transgenic mice where tau is highly overexpressed axonal dilations are seen, which contain transported cargo such as neurofilaments, tublin and vesicles. [21] [22] [23] This indicates that axonal transport is disrupted in these mice and indeed one group demonstrated reduced transportation of horseradish peroxidase in their model. 21 However, all of these mice exhibited an age-dependent progressive axonopathy, which makes it difficult to conclude that there is reduced axonal transport and one cannot therefore easily disentangle the effects of neuronal death from a primary effect of tau on transport. Interestingly, these transgenic mice also showed profound motor dysfunction, which could be attributed to the tau effect on axonal transport in motor neurons (as our results would indicate); however, here too, the concomitant neurodegeneration makes it difficult to conclude that the motor dysfunction arose initially because of a taumediated disruption of axonal transport. Our results support the observations made in these murine models, and extend them by demonstrating that over-expression of tau can lead to physiologically significant neuronal dysfunction before causing neurodegeneration.
Hyperphosphorylation: the mechanism by which tau disrupts axonal transport? The earliest abnormality detected in pretangle neurons in AD is an increase in tau phosphorylation and a redistribution to the somatic compartment. 25 An important question is whether this increase in phosphorylation is a primary pathogenic event 28 or whether it is a compensatory process to some other process-perhaps an increase in the level of tau expression. 24 Compensatory tau phosphorylation would be supported by the findings of others, 7, 26 who showed that increased phosphorylation of tau rescued the axonopathy and axonal transport disruption induced by overexpression of wt tau in a murine model. However, our findings argue against this as reducing phosphorylation of tau even in those animals that express tau alone reduces axonal transport defects, suggesting that it is not just prolonged and induced hyperphosphorylation (as in the vGFP Â tau/sgg* co-expressing animals) but endogenous phosphorylation (which would have occurred in vGFP Â tau animals) that is deleterious. Instead, our findings suggest that even modest tau phosphorylation can reduce axonal transport.
The findings of Jackson et al 4 that hyperphosphorylation of tau stimulates its aggregation in Drosophila suggests that tau aggregates may be responsible for interfering with axonal transport in our model. However, we failed to observe tau aggregates in the motor neurons concurrent with axonal transport disruption. It is possible that small aggregates of tau are present in our models and we have failed to detect these using electron microscopy. Alternatively, it is possible that tau aggregates are present only when tau is expressed in certain neuronal populations or to a greater extent than in our model. We are currently addressing these questions and yet it is clear that there is a gross defect in axonal transport and a subsequent phenotype in the absence of tau aggrgegates at the mcirospic level-much as in very early pre-tangle neurons in AD brain.
The means by which phosphorylation exacerbates the tau effect on axonal transport remains to be determined. 28 Whatever the mechanism, these observations in a living intact animal model suggest that an increase in tau phosphorylation induces an abnormal phenotype that requires neither tau aggregation nor neuronal death to cause neuronal dysfunction. The implications for treatment of AD and other tauopathies are obvious: our model predicts that inhibitors of tau phosphorylation, 27 such as GSK-3b inhibitors may be useful in both AD and fronto-temporal dementia.
Disruption of axonal transport-relevance to Alzheimer's disease There are other links between axonal transport and proteins implicated in the pathogenesis of AD. 29, 30 Amyloid precursor protein (APP) has recently been shown to be a kinesin receptor, linking kinesin motors to a subset of cargo for transcytosis. 31, 32 Previously, overexpression of APPL, the Drosophila APP homolog, had been shown to induce retention of synaptic cargo within segmental nerves of Drosophila third instar larvae, 33 indicating a disruption of axonal transport. Interestingly, these authors found that over-expression of bovine tau induced a similar retention of axonal cargo, but this became synergistically enhanced when the two proteins were coexpressed. The finding that APP mediates the kinesin-dependent transportation of presenilin, 32 the most common cause of familial early onset AD, further strengthens the axonal transport-AD link via APP. These studies raise the intriguing possibility that tau and APP are both involved in the pathogenesis of AD by virtue of the fact that they both influence axonal transport and this very basic housekeeping activity may be what is preferentially affected in the very early stages of the disease.
Conclusion
Much of the research in AD and related tauopathies has concentrated on how the pathological hallmarks of these diseases arise, and how they lead to neuronal death. While it is likely that neuronal loss contributes to clinical symptoms, little attention has been paid to the possibility that neuronal dysfunction may result from changes preceding the development of the pathological hallmarks. The results presented here suggest that a disruption in axonal transport is one such early detrimental consequence that appears when tau protein is overexpressed. As we have shown that this phenotype is GSK-3b dependent, it follows that evidence is provided for the first time GSK-3b inhibition rescues defects in Drosophila A Mudher et al in vivo to suggest that GSK-3b inhibitors are a valid therapeutic strategy in the tauopathies.
